Chemical genetics: Exploring the role of the proteasome in cell biology using natural products and other small molecule proteasome inhibitors

Journal of Medicinal Chemistry

Volumn 51, Issue 9, 2008, Pages 2600-2605

  Kyung, Bo Kim ^a   Crews, Craig M ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CELASTROL; EPIGALLOCATECHIN GALLATE; EPOXOMICIN; FLAVONOID; GENISTEIN; LACTACYSTIN; MYRICETIN; NATURAL PRODUCT; PRISTIMEROL; PROTEASOME INHIBITOR; QUERCETIN; SALINOSPORAMIDE A; TERPENOID; TRITERPENOID; WITHAFERIN A;

ANTINEOPLASTIC ACTIVITY; BONE GROWTH; CELL PROLIFERATION; CHEMICAL GENETICS; DRUG MECHANISM; HUMAN; INFLAMMATION; REVIEW;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOLOGICAL PRODUCTS; BONE DEVELOPMENT; BONE MORPHOGENETIC PROTEINS; CELL PROLIFERATION; GENETIC TECHNIQUES; HUMANS; INFLAMMATION; NF-KAPPA B; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; SIGNAL TRANSDUCTION;

EID: 42949152860     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070421s     Document Type: Review

References (67)

1. (a) Henry, C. M. High hopes for RNA interference. Chem. Eng. News 2003, 81, 32-36.
2. (b) Jackson, A. L.; Bartz, S. R.; Schelter, J.; Kobayashi, S. V.; Burchard, J.; Mao, M.; Li, B.; Cavet, G.; Linsley, P. S. Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. 2003, 21, 635-637.
3. Schreiber, S. L. Chemical genetics resulting from a passion for synthetic organic chemistry. Bioorg. Med. Chem. 1998, 6, 1127-1152.
4. Adams, J. Development of the proteasome inhibitor PS-341. Oncologist 2002, 7, 9-16.
5. Ciechanover, A.; Orian, A.; Schwartz, A. L. Ubiquitin-mediated proteolysis: biological regulation via destruction. BioEssays 2000, 22, 442-451.
6. (a) Myung, J.; Kim, K. B.; Crews, C. M. The ubiquitin-proteasome pathway and proteasome inhibitors. Med. Res. Rev. 2001, 21, 245-73.
7. (b) Kim, K. B.; Crews, C. M. Natural Product and Synthetic Proteasome Inhibitors. In Cancer Drug Discovery and Development: Proteasome Inhibitors in Cancer Therapy; Adams, J., Ed.; Humana Press Inc.: Totowa, NJ, 2003; pp 47-63.
8. Palombella, V. J.; Rando, O. J.; Goldberg, A. L.; Maniatis, T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994, 78, 773-785.
9. (a) Bogyo, M.; McMaster, J. S.; Gaczynska, M.; Tortorella, D.; Goldberg, A. L.; Ploegh, H. Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homolog HslV by a new class of inhibitors. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 6629-6634.
10. (b) Bogyo, M.; Shin, S.; McMaster, J. S.; Ploegh, H. L. Substrate binding and sequence preference of the proteasome revealed by active-site-directed affinity probes. Chem. Biol. 1998, 5, 307-320.
11. Omura, S.; Fujimoto, T.; Otoguro, K.; Matsuzaki, K.; Moriguchi, R.; Tanaka, H.; Sasaki, Y. Lactacystin, a novel microbial metabolite, induces neuritogenesis of neuroblastoma cells. J. Antibiot. (Tokyo) 1991, 44, 113-116.
12. Hanada, M.; Sugawara, K.; Kaneta, K.; Toda, S.; Nishiyama, Y.; Tomita, K.; Yamamoto, H.; Konishi, M.; Oki, T. Epoxomicin, a new antitumor agent of microbial origin. J. Antibiot. (Tokyo) 1992, 45, 1746-1752.
13. (a) Tsuchiya, K.; Kobayashi, S.; Nishikiori, T.; Nakagawa, T.; Tatsuta, K. Epopromycins, novel cell wall synthesis inhibitors of plant protoplast produced by Streptomyces sp. NK04000. J. Antibiot. (Tokyo) 1997, 50, 261-263.
14. (b) Koguchi, Y.; Kohno, J.; Nishio, M.; Takahashi, K.; Okuda, T.; Ohnuki, T.; Komatsubara, S. TMC-95A, B, C, and D, novel proteasome inhibitors produced by Apiospora montagnei Sacc. TC 1093. Taxonomy, production, isolation, and biological activities. J. Antibiot. (Tokyo) 2000, 53, 105-109.
15. (c) Koguchi, Y.; Kohno, J.; Suzuki, S.; Nishio, M.; Takahashi, K.; Ohnuki, T.; Komatsubara, S. TMC-86A, B and TMC-96, new proteasome inhibitors from Streptomyces sp. TC 1084 and Saccharothrix sp. TC 1094. I. Taxonomy, fermentation, isolation, and biological activities. J. Antibiot. (Tokyo) 1999, 52, 1069-76.
16. (d) Sugawara, K.; Hatori, M.; Nishiyama, Y.; Tomita, K.; Kamei, H.; Konishi, M.; Oki, T. Eponemycin, a new antibiotic active against B16 melanoma. I. Production, isolation, structure and biological activity. J. Antibiot. (Tokyo) 1990, 43, 8-18.
17. Elliott, P. J.; Ross, J. S. The proteasome: a new target for novel drug therapies. Am. J. Clin. Pathol. 2001, 116, 637-646.
18. Wang, X.; Luo, H.; Chen, H.; Duguid, W.; Wu, J. Role of proteasomes in T cell activation and proliferation. J. Immunol. 1998, 160, 788-801.
19. (a) Fenteany, G.; Standaert, R. F.; Lane, W. S.; Choi, S.; Corey, E. J.; Schreiber, S. L. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 1995, 268, 726-731.
20. (b) Bernardi, R.; Liebermann, D. A.; Hoffman, B. Cdc25A stability is controlled by the ubiquitin-proteasome pathway during cell cycle progression and terminal differentiation. Oncogene 2000, 19, 2447-2454.
21. (c) Hershko, A. Roles of ubiquitin-mediated proteolysis in cell cycle control. Curr. Opin. Cell Biol. 1997, 9, 788-799.
22. (a) Yew, P. R. Ubiquitin-mediated proteolysis of vertebrate G1- and S-phase regulators. J. Cell. Physiol. 2001, 187, 1-10.
23. (b) Evans, T.; Rosenthal, E. T.; Youngblom, J.; Distel, D.; Hunt, T. Cyclin: a protein specified by maternal mRNA in sea urchin eggs that is destroyed at each cleavage division. Cell 1983, 33, 389-396.
24. (c) Glotzer, M.; Murray, A. W.; Kirschner, M. W. Cyclin is degraded by the ubiquitin pathway. Nature 1991, 349, 132-138.
25. (a) Hershko, A.; Ciechanover, A. The ubiquitin system. Annu. Rev. Biochem. 1998, 67, 425-79.
26. (b) Pagano, M.; Tam, S. W.; Theodoras, A. M.; Beer-Romero, P.; Del Sal, G.; Chau, V.; Yew, P. R.; Draetta, G. F.; Rolfe, M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995, 269, 682-685.
27. (a) Koepp, D. M.; Harper, J. W.; Elledge, S. J. How the cyclin became a cyclin: regulated proteolysis in the cell cycle. Cell 1999, 97, 431-434.
28. (b) Nakayama, K. I.; Nakayama, K. Regulation of the cell cycle by SCF-type ubiquitin ligases. Semin. Cell Dev. Biol. 2005, 16, 323-333.
29. Kubbutat, M. H.; Jones, S. N.; Vousden, K. H. Regulation of p53 stability by Mdm2. Nature 1997, 387, 299-303.
30. Lavin, M. F.; Gueven, N. The complexity of p53 stabilization and activation. Cell Death Differ. 2006, 13, 941-950.
31. (a) Freedman, D. A.; Wu, L.; Levine, A. J. Functions of the MDM2 oncoprotein. Cell. Mol. Life Sci. 1999, 55, 96-107.
32. (b) Brooks, C. L.; Gu, W. p53 ubiquitination: Mdm2 and beyond. Mol. Cell 2006, 21, 307-315.
33. Wagenknecht, B.; Hermisson, M.; Eitel, K.; Weller, M. Proteasome inhibitors induce p53/p21-independent apoptosis in human glioma cells. Cell. Physiol. Biochem. 1999, 9, 117-125.
34. (a) Jesenberger, V.; Jentsch, S. Deadly encounter: ubiquitin meets apoptosis. Nat. Rev. Mol. Cell Biol. 2002, 3, 112-121.
35. (b) Cory, S.; Adams, J. M. The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2002, 2, 647-656.
36. Zhang, H. G.; Wang, J.; Yang, X.; Hsu, H. C.; Mountz, J. D. Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene 2004, 23, 2009-2015.
37. Marshansky, V.; Wang, X.; Bertrand, R.; Luo, H.; Duguid, W.; Chinnadurai, G.; Kanaan, N.; Vu, M. D.; Wu, J. Proteasomes modulate balance among proapoptotic and antiapoptotic Bcl-2 family members and compromise functioning of the electron transport chain in leukemic cells. J. Immunol. 2001, 166, 3130-3142.
38. Breitschopf, K.; Zeiher, A. M.; Dimmeier, S. Ubiquitin-mediated degradation of the proapoptotic active form of bid. A functional consequence on apoptosis induction. J. Biol. Chem. 2000, 275, 21648-21652.
39. Li, B.; Dou, Q. P. Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 3850-3855.
40. Thomas, M.; Banks, L. Inhibition of Bak-induced apoptosis by HPV-18 E6. Oncogene 1998, 17, 2943-2954.
41. (a) Chen, D.; Daniel, K. G.; Chen, M. S.; Kuhn, D. J.; Landis-Piwowar, K. R.; Dou, Q. P. Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells. Biochem. Pharmacol. 2005, 69, 1421-1432.
42. (b) Chen, D.; Daniel, K. G.; Kuhn, D. J.; Kazi, A.; Bhuiyan, M.; Li, L.; Wang, Z.; Wan, S. B.; Lam, W. H.; Chan, T. H.; Dou, Q. P. Green tea and tea polyphenols in cancer prevention. Front. Biosci. 2004, 9, 2618-2631.
43. (c) Yang, H.; Shi, G.; Dou, Q. P. The tumor proteasome is a primary target for the natural anticancer compound Withaferin A isolated from "Indian winter cherry. Mol. Pharmacol. 2007, 71, 426-437.
44. (d) Yang, H.; Chen, D.; Cui, Q. C.; Yuan, X.; Dou, Q. P. Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine", is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res. 2006, 66, 4758-4765.
45. (e) Kazi, A.; Daniel, K. G.; Smith, D. M.; Kumar, N. B.; Dou, Q. P. Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein. Biochem. Pharmacol. 2003, 66, 965-976.
46. Karin, M.; Ben-Neriah, Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu. Rev. Immunol. 2000, 18, 621-663.
47. (a) Arlt, A.; Schafer, H. NFkappaB-dependent chemoresistance in solid tumors. Int. J. Clin. Pharmacol. Ther. 2002, 40, 336-347.
48. (b) Cusack, J. C.; Liu, R.; Baldwin, A. S. NF-kappa B and chemoresistance: potentiation of cancer drugs via inhibition of NF-kappa B. Drug Resist. Updates 1999, 2, 271-273.
49. Cusack, J. C., Jr.; Liu, R.; Houston, M.; Abendroth, K.; Elliott, P. J.; Adams, J.; Baldwin, A. S., Jr. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res. 2001, 61, 3535-3540.
50. (a) ten Dijke, P. Bone morphogenetic protein signal transduction in bone. Curr. Med. Res. Opin. 2006, 22, S7-S11.
51. (b) Massague, J.; Seoane, J.; Wotton, D. Smad transcription factors. Genes Dev. 2005, 19, 2783-2810.
52. Urist, M. R. Bone: formation by autoinduction. Science 1965, 150, 893-899.
53. Urist, M. R.; Huo, Y. K.; Brownell, A. G.; Hohl, W. M.; Buyske, J.; Lietze, A.; Tempst, P.; Hunkapiller, M.; DeLange, R. J. Purification of bovine bone morphogenetic protein by hydroxyapatite chromatography. Proc. Natl. Acad. Sci. U.S.A. 1984, 81, 371-375.
54. Cao, X.; Chen, D. The BMP signaling and in vivo bone formation. Gene 2005, 357, 1-8.
55. Re'em-Kalma, Y.; Lamb, T.; Frank, D. Competition between noggin and bone morphogenetic protein 4 activities may regulate dorsalization during Xenopus development. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 12141-12145.
56. Garrett, I. R.; Chen, D.; Gutierrez, G.; Zhao, M.; Escobedo, A.; Rossini, G.; Harris, S. E.; Gallwitz, W.; Kim, K. B.; Hu, S.; Crews, C. M.; Mundy, G. R. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J. Clin. Invest. 2003, 111, 1771-1782.
57. Fujii, M.; Takeda, K.; Imamura, T.; Aoki, H.; Sampath, T. K.; Enomoto, S.; Kawabata, M.; Kato, M.; Ichijo, H.; Miyazono, K. Roles of bone morphogenetic protein type I receptors and Smad proteins in osteoblast and chondroblast differentiation. Mol. Biol. Cell 1999, 10, 3801-3813.
58. (a) Wang, T. The 26S proteasome system in the signaling pathways of TGF-beta superfamily. Front. Biosci. 2003, 8, d1109-d1127.
59. (b) Gruendler, C.; Lin, Y.; Farley, J.; Wang, T. Proteasomal degradation of Smad1 induced by bone morphogenetic proteins. J. Biol. Chem. 2001, 276, 46533-46543.
60. (c) Zhao, M.; Qiao, M.; Harris, S. E.; Oyajobi, B. O.; Mundy, G. R.; Chen, D. Smurf1 inhibits osteoblast differentiation and bone formation in vitro and in vivo. J. Biol. Chem. 2004, 279, 12854-12859.
61. (a) Figueiredo-Pereira, M. E.; Chen, W. E.; Li, J.; Johdo, O. The antitumor drug aclacinomycin A, which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20 S proteasome. J. Biol. Chem. 1996, 271, 16455-16459.
62. (b) Kisselev, A. F.; Callard, A.; Goldberg, A. L. Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J. Biol. Chem. 2006, 281, 8582-8590.
63. (a) Diaz-Hernandez, M.; Hernandez, F.; Martin-Aparicio, E.; Gomez-Ramos, P.; Moran, M. A.; Castano, J. G.; Ferrer, I.; Avila, J.; Lucas, J. J. Neuronal induction of the immunoproteasome in Huntington's disease. J. Neurosci. 2003, 23, 11653-11661.
64. (b) Piccinini, M.; Mostert, M.; Croce, S.; Baldovino, S.; Papotti, M.; Rinaudo, M. T. Interferon-gamma-inducible subunits are incorporated in human brain 20S proteasome. J. Neuroimmunol. 2003, 135, 135-140.
65. (c) Mishto, M.; Bellavista, E.; Santoro, A.; Stolzing, A.; Ligorio, C.; Nacmias, B.; Spazzafumo, L.; Chiappelli, M.; Licastro, F.; Sorbi, S.; Pession, A.; Ohm, T.; Grune, T.; Franceschi, C. Immunoproteasome and LMP2 polymorphism in aged and Alzheimer's disease brains. Neurobiol. Aging 2006, 27, 54-66.
66. (d) Orlowski, R. Z. The ubiquitin proteasome pathway from bench to bedside. Hematology (Am. Soc. Hematol. Educ. Program) 2005, 220-225.
67. (e) Ho, Y. K.; Bargagna-Mohan, P.; Mohan, R.; Kim, K. B. LMP2-specific inhibitors: novel chemical genetic tools for proteasome biology. Chem. Biol. 2007, 14, 419-430.